A reconstituted human antibody against a human interleukin 6 receptor (IL-6R), which is composed of: (A) an L chain composed of (1) the C region of a human L chain and (2) the V region of an L chain comprising the framework region (FR) of a human L chain and the complementarity-determining region (C ...
The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized anti ...
Chimerized and humanized versions of anti EGF receptor antibody 225 and fragments thereof for treatment of tumors.
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aß in the brain of a patient. Preferred agents include antibodies, e.g., humanized antibodies.
Recombinant antibody proteins are provided that specifically bind fibroblast activation protein alpha (FAP alpha ) and comprise framework modifications resulting in the improved producibility in host cells. The invention also relates to the use of said antibodies for diagnostic and therapeutic purpo ...
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A&bgr; in the brain of a patient. Preferred agents include humanized antibodies.
The invention relates to reshaped human monoclonal antibodies directed against isotypic determinants of immunoglobulin E (IgE), direct equivalents and derivatives of said antibodies. The molecules of the invention are useful for diagnostics, prophylaxis and treatment of allergy.
Humanized forms of an anti-CRIPTO antibody and portions thereof. In one embodiment, the variable regions of these antibodies or polypeptides comprising them (e.g., full-length antibodies or domain deleted antibodies) can be used to treat disorders, such as cancer.
[en] The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Abeta in the brain of a patient. Preferred agents include humanized antibodies.